NCT04917887 is a clinical trial in Dystrophic Epidermolysis Bullosa, sponsored by Krystal Biotech, Inc..

Who is sponsoring NCT04917887?

NCT04917887 is sponsored by Krystal Biotech, Inc..

What condition does NCT04917887 study?

NCT04917887 studies Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa.

Is NCT04917887 still recruiting?

NCT04917887 is currently recruiting now. Last updated 8 June 2021.

Last reviewed 2021-06-08 · How we verify

NCT04917887

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Follow-up Protocol

Recruiting now Last updated 8 June 2021

What this trial tests

trial in Dystrophic Epidermolysis Bullosa in 50 participants. Currently enrolling.

Timeline

25 May 2021

Primary endpoint
25 May 2028

25 May 2028

Quick facts

Lead sponsor	Krystal Biotech, Inc.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	50
Start date	25 May 2021
Primary completion	25 May 2028
Estimated completion	25 May 2028
Sites	3 locations across United States

Conditions studied

Dystrophic Epidermolysis Bullosa — all drugs for Dystrophic Epidermolysis Bullosa →
Recessive Dystrophic Epidermolysis Bullosa — all drugs for Recessive Dystrophic Epidermolysis Bullosa →
Dominant Dystrophic Epidermolysis Bullosa — all drugs for Dominant Dystrophic Epidermolysis Bullosa →

Sponsor

Krystal Biotech, Inc. — full company profile →

Who can join

6 Months and older, any sex, with Dystrophic Epidermolysis Bullosa or Recessive Dystrophic Epidermolysis Bullosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.
Bischof J, Hierl M, Koller U. · · 2024 · cited 20× · PMID 38396920 · DOI 10.3390/ijms25042243
CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.
Wang X, Wang X, Li Y, A S, et al · · 2023 · cited 9× · PMID 38027067 · DOI 10.1016/j.omtm.2023.101134
Treatment of Epidermolysis Bullosa and Future Directions: A Review.
Danescu S, Negrutiu M, Has C. · · 2024 · cited 7× · PMID 39090514 · DOI 10.1007/s13555-024-01227-8

Verify or expand the search:

Other recruiting trials for Dystrophic Epidermolysis Bullosa

Currently open trials in the same condition.

NCT06594393 — A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study · Phase 2 · recruiting
NCT07230223 — Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa · Phase 1, PHASE2 · recruiting
NCT05157958 — Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa · Phase 2 · recruiting

Other Krystal Biotech, Inc. trials

Trials by the same sponsor.

NCT05095246 — A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis · Phase 1 · withdrawn
NCT04917874 — A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa · Phase 3 · completed
NCT04540900 — A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) fo · Phase 1 · active not recruiting
NCT04491604 — Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB · Phase 3 · completed
NCT03536143 — A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04917887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Krystal Biotech, Inc.
Last refreshed: 8 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04917887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing